English
Insider transactions
EDGARCompass Therapeutics, Inc.
Transactions reported by directors, officers and 10% owners on SEC Forms 3, 4 and 5, read from each filing’s XML. Codes and their wording are the SEC’s own.
A Form 4 is due within two business days of the transaction, so the most recent trades may not be filed yet.
Window: transactions dated on or after 2025-11-15.
- Open-market purchases (code P)
- 4 transactions, 62,500 shares
- Sum of shares × price per share: 96,850
- Open-market sales (code S)
- 0 transactions, — shares
Totals add the filed transactions listed; they are counts of what was reported, not a measure of direction.
Showing 1–25 of 25
| Date | Reporting owner | Code | Acquired or disposed | Shares | Price per share, as filed | Value (derived) | Shares owned after | Direct or indirect | Rule 10b5-1 box | Notes | Source |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-10-01 Filed 2026-10-02 | Lerner Neil Officer: Chief Accounting Officer | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 20,000 | 0.92 | 18,400Derived: shares × price per share. Exact value 18400.00. | 420,000 | Direct (D) | No | F1
| Open filing 0001171843-26-006349 Read from the filing’s XML Dispute this row |
| 2026-09-24 Filed 2026-09-25 | Lerner Neil Officer: Chief Accounting Officer | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 2,500 | 1.14 | 2,850Derived: shares × price per share. Exact value 2850.00. | 400,000 | Direct (D) | No | F1
| Open filing 0001171843-26-006235 Read from the filing’s XML Dispute this row |
| 2026-04-29 Filed 2026-04-30 | Lerner Neil Officer: Chief Accounting Officer | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 15,000 | 1.89 | 28,350Derived: shares × price per share. Exact value 28350.00. | 397,500 | Direct (D) | No | F1
| Open filing 0001171843-26-002894 Read from the filing’s XML Dispute this row |
| 2026-04-29 Filed 2026-04-30 | Anderman Jonathan Officer: General Counsel | POpen market or private purchase of non-derivative or derivative security | Acquired (A) | 25,000 | 1.89 | 47,250Derived: shares × price per share. Exact value 47250.00. | 196,000 | Direct (D) | No | F1
| Open filing 0001171843-26-002893 Read from the filing’s XML Dispute this row |
| 2026-04-29 Filed 2026-04-29 | Anderman Jonathan Officer: General Counsel | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 25,000 | 1.89 | 47,250Derived: shares × price per share. Exact value 47250.00. | 196,000 | Direct (D) | No | F1
| Open filing 0001171843-26-002840 Read from the filing’s XML Dispute this row |
| 2026-04-29 Filed 2026-04-29 | Lerner Neil Officer: Chief Accounting Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 15,000 | 1.89 | 28,350Derived: shares × price per share. Exact value 28350.00. | 397,500 | Direct (D) | No | F1
| Open filing 0001171843-26-002834 Read from the filing’s XML Dispute this row |
| 2026-02-08 Filed 2026-02-10 | Schuetz Thomas J. Director · Officer: CHIEF EXECUTIVE OFFICER | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 36,687 | 6.52 | 239,199.24Derived: shares × price per share. Exact value 239199.24. | 6,603,336 | Direct (D) | No | F1, F2
| Open filing 0001171843-26-000722 Read from the filing’s XML Dispute this row |
| 2026-01-09 Filed 2026-01-12 | Schuetz Thomas J. Director · Officer: CHIEF EXECUTIVE OFFICER | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 46,777 | 5.35 | 250,256.95Derived: shares × price per share. Exact value 250256.95. | 6,640,023 | Direct (D) | No | F1, F2
| Open filing 0001171843-26-000205 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | GRAY MARY ANN Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 90,000 | 0 | — | 90,000 | Direct (D) | No | F1
| Open filing 0001171843-26-000055 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Shin Barry Officer: CFO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 125,000 | 5.17 | 646,250Derived: shares × price per share. Exact value 646250.00. | 525,000 | Direct (D) | No | F1, F2
| Open filing 0001171843-26-000062 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Shin Barry Officer: CFO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 670,000 | 0 | — | 670,000 | Direct (D) | No | F3
| Open filing 0001171843-26-000062 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Schuetz Thomas J. Director · Officer: CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 250,000 | 5.17 | 1,292,500Derived: shares × price per share. Exact value 1292500.00. | 6,686,800 | Direct (D) | No | F1, F2
| Open filing 0001171843-26-000060 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Schuetz Thomas J. Director · Officer: CEO | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 2,000,000 | 0 | — | 2,000,000 | Direct (D) | No | F3
| Open filing 0001171843-26-000060 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | LINDAHL RICHARD S Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 90,000 | 0 | — | 90,000 | Direct (D) | No | F1
| Open filing 0001171843-26-000058 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Lerner Neil Officer: Chief Accounting Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 62,500 | 5.17 | 323,125Derived: shares × price per share. Exact value 323125.00. | 382,500 | Direct (D) | No | F1, F2
| Open filing 0001171843-26-000056 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Lerner Neil Officer: Chief Accounting Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 435,000 | 0 | — | 435,000 | Direct (D) | No | F3
| Open filing 0001171843-26-000056 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Boylan James P Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 90,000 | 0 | — | 90,000 | Direct (D) | No | F1, F2
| Open filing 0001171843-26-000054 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Prasad Arjun Officer: Chief Commercial Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 1,000,000 | 0 | — | 1,000,000 | Direct (D) | No | F1, F2
| Open filing 0001171843-26-000059 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Sirard Cynthia Officer: Chief Medical Officer | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 1,000,000 | 0 | — | 1,000,000 | Direct (D) | No | F1, F2
| Open filing 0001171843-26-000061 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Ferneau Philip Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 90,000 | 0 | — | 90,000 | Direct (D) | No | F1
| Open filing 0001171843-26-000052 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Chiniara Ellen Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 90,000 | 0 | — | 90,000 | Direct (D) | No | F1
| Open filing 0001171843-26-000057 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | GORDON CARL L Director | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 90,000 | 0 | — | 90,000 | Direct (D) | No | F1, F2
| Open filing 0001171843-26-000053 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Anderman Jonathan Officer: General Counsel | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 150,000 | 5.17 | 775,500Derived: shares × price per share. Exact value 775500.00. | 171,000 | Direct (D) | No | F1, F2
| Open filing 0001171843-26-000051 Read from the filing’s XML Dispute this row |
| 2026-01-02 Filed 2026-01-05 | Anderman Jonathan Officer: General Counsel | AGrant, award or other acquisition pursuant to Rule 16b-3(d) | Acquired (A) | 720,000 | 0 | — | 720,000 | Direct (D) | No | F3
| Open filing 0001171843-26-000051 Read from the filing’s XML Dispute this row |
| 2025-11-16 Filed 2025-11-18 | Schuetz Thomas J. Director · Officer: CHIEF EXECUTIVE OFFICER | FPayment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 | Disposed (D) | 44,025 | 4.83 | 212,640.75Derived: shares × price per share. Exact value 212640.75. | 6,436,800 | Direct (D) | No | F1, F2
| Open filing 0001171843-25-007400 Read from the filing’s XML Dispute this row |
Institutional holders (Form 13F)
No Form 13F position in this issuer is placed in the store. A holder not yet linked or not yet filed is absent, not zero.
5% holders (Schedule 13D and 13G)
Schedules filed in the SEC’s structured format (late 2024 onward) are read here. Earlier schedules are free text and are not read.
| Holder | Percent of class | Shares held | Event date | Form | Source |
|---|---|---|---|---|---|
| STATE STREET CORPORATION COMMON STOCK | 4.3 | 7,737,938.00 | 09/30/2026 Filed 2026-11-10 | SCHEDULE 13G | Open filing 0000093751-26-000634 Dispute this row |
| Vivo Opportunity Fund Holdings, L.P. Common Stock, par value $0.0001 per share | 4.0 | 7,207,573.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-26-089989 Dispute this row |
| Vivo Opportunity, LLC Common Stock, par value $0.0001 per share | 4.0 | 7,207,573.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-26-089989 Dispute this row |
| Vivo Opportunity Cayman Fund, L.P. Common Stock, par value $0.0001 per share | 0.3 | 549,487.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-26-089989 Dispute this row |
| Vivo Opportunity Cayman, LLC Common Stock, par value $0.0001 per share | 0.3 | 549,487.00 | 06/30/2026 Filed 2026-08-14 | SCHEDULE 13G/AAmendment 1 | Open filing 0001213900-26-089989 Dispute this row |
| STATE STREET CORPORATION COMMON STOCK | 5.5 | 9,953,653.00 | 06/30/2026 Filed 2026-08-07 | SCHEDULE 13G | Open filing 0000093751-26-000440 Dispute this row |
| BIOTECHNOLOGY VALUE FUND L P Common Stock, $0.0001 par value per share | 2.3 | 4,142,020.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0000921895-26-001388 Dispute this row |
| BVF I GP LLC Common Stock, $0.0001 par value per share | 2.3 | 4,142,020.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0000921895-26-001388 Dispute this row |
| BIOTECHNOLOGY VALUE FUND II LP Common Stock, $0.0001 par value per share | 1.7 | 3,028,951.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0000921895-26-001388 Dispute this row |
| BVF II GP LLC Common Stock, $0.0001 par value per share | 1.7 | 3,028,951.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0000921895-26-001388 Dispute this row |
| Biotechnology Value Trading Fund OS LP Common Stock, $0.0001 par value per share | 0.3 | 476,311.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0000921895-26-001388 Dispute this row |
| BVF Partners OS Ltd. Common Stock, $0.0001 par value per share | 0.3 | 476,311.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0000921895-26-001388 Dispute this row |
| BVF GP HOLDINGS LLC Common Stock, $0.0001 par value per share | 4.0 | 7,170,971.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0000921895-26-001388 Dispute this row |
| BVF PARTNERS L P/IL Common Stock, $0.0001 par value per share | 4.3 | 7,764,842.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0000921895-26-001388 Dispute this row |
| BVF INC/IL Common Stock, $0.0001 par value per share | 4.3 | 7,764,842.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0000921895-26-001388 Dispute this row |
| LAMPERT MARK N Common Stock, $0.0001 par value per share | 4.3 | 7,764,842.00 | 03/31/2026 Filed 2026-05-15 | SCHEDULE 13G/AAmendment 1 | Open filing 0000921895-26-001388 Dispute this row |
| Blackstone Annex Master Fund L.P. Common Stock, $0.0001 par value per share | 1.4 | 2,447,820 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193125-26-051513 Dispute this row |
| Spruce Street Aggregator L.P. Common Stock, $0.0001 par value per share | 2.1 | 3,678,362 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193125-26-051513 Dispute this row |
| Blackstone Alternative Asset Management Associates LLC Common Stock, $0.0001 par value per share | 3.4 | 6,126,182 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193125-26-051513 Dispute this row |
| Blackstone Holdings II L.P. Common Stock, $0.0001 par value per share | 3.4 | 6,126,182 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193125-26-051513 Dispute this row |
| Blackstone Holdings I/II GP L.L.C. Common Stock, $0.0001 par value per share | 3.4 | 6,126,182 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193125-26-051513 Dispute this row |
| Blackstone Inc. Common Stock, $0.0001 par value per share | 3.4 | 6,126,182 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193125-26-051513 Dispute this row |
| Blackstone Group Management L.L.C. Common Stock, $0.0001 par value per share | 3.4 | 6,126,182 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193125-26-051513 Dispute this row |
| Stephen A. Schwarzman Common Stock, $0.0001 par value per share | 3.4 | 6,126,182 | 12/31/2025 Filed 2026-02-13 | SCHEDULE 13G/AAmendment 1 | Open filing 0001193125-26-051513 Dispute this row |
| BlackRock, Inc. Common Stock | 5.2 | 9,271,644 | 12/31/2025 Filed 2026-01-21 | SCHEDULE 13G | Open filing 0002012383-26-000660 Dispute this row |
| BIOTECHNOLOGY VALUE FUND L P Common Stock, $0.0001 par value per share | 2.7 | 4,673,550.00 | 10/22/2025 Filed 2025-10-29 | SCHEDULE 13G | Open filing 0000921895-25-002825 Dispute this row |
| BVF I GP LLC Common Stock, $0.0001 par value per share | 2.7 | 4,673,550.00 | 10/22/2025 Filed 2025-10-29 | SCHEDULE 13G | Open filing 0000921895-25-002825 Dispute this row |
| BIOTECHNOLOGY VALUE FUND II LP Common Stock, $0.0001 par value per share | 2.0 | 3,396,894.00 | 10/22/2025 Filed 2025-10-29 | SCHEDULE 13G | Open filing 0000921895-25-002825 Dispute this row |
| BVF II GP LLC Common Stock, $0.0001 par value per share | 2.0 | 3,396,894.00 | 10/22/2025 Filed 2025-10-29 | SCHEDULE 13G | Open filing 0000921895-25-002825 Dispute this row |
| Biotechnology Value Trading Fund OS LP Common Stock, $0.0001 par value per share | 0.3 | 542,486.00 | 10/22/2025 Filed 2025-10-29 | SCHEDULE 13G | Open filing 0000921895-25-002825 Dispute this row |
| BVF Partners OS Ltd. Common Stock, $0.0001 par value per share | 0.3 | 542,486.00 | 10/22/2025 Filed 2025-10-29 | SCHEDULE 13G | Open filing 0000921895-25-002825 Dispute this row |
| BVF GP HOLDINGS LLC Common Stock, $0.0001 par value per share | 4.7 | 8,070,444.00 | 10/22/2025 Filed 2025-10-29 | SCHEDULE 13G | Open filing 0000921895-25-002825 Dispute this row |
| BVF PARTNERS L P/IL Common Stock, $0.0001 par value per share | 5.1 | 8,750,000.00 | 10/22/2025 Filed 2025-10-29 | SCHEDULE 13G | Open filing 0000921895-25-002825 Dispute this row |
| BVF INC/IL Common Stock, $0.0001 par value per share | 5.1 | 8,750,000.00 | 10/22/2025 Filed 2025-10-29 | SCHEDULE 13G | Open filing 0000921895-25-002825 Dispute this row |
| LAMPERT MARK N Common Stock, $0.0001 par value per share | 5.1 | 8,750,000.00 | 10/22/2025 Filed 2025-10-29 | SCHEDULE 13G | Open filing 0000921895-25-002825 Dispute this row |
| TANG CAPITAL MANAGEMENT, LLC Common Stock, par value $0.0001 per share | 9.99 | 17,176,510.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001214659-25-016688 Dispute this row |
| KEVIN TANG Common Stock, par value $0.0001 per share | 9.99 | 17,176,510.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001214659-25-016688 Dispute this row |
| TANG CAPITAL PARTNERS, LP Common Stock, par value $0.0001 per share | 5.98 | 10,274,944.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001214659-25-016688 Dispute this row |
| TANG CAPITAL PARTNERS INTERNATIONAL, LP Common Stock, par value $0.0001 per share | 3.24 | 5,568,566.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001214659-25-016688 Dispute this row |
| TANG CAPITAL PARTNERS III, INC Common Stock, par value $0.0001 per share | 0.58 | 999,750.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001214659-25-016688 Dispute this row |
| TANG CAPITAL PARTNERS IV, INC Common Stock, par value $0.0001 per share | 0.19 | 333,250.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001214659-25-016688 Dispute this row |
| Vivo Opportunity Fund Holdings, L.P. Common Stock, par value $0.0001 per share | 5.1 | 8,995,979.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G | Open filing 0001213900-25-111134 Dispute this row |
| Vivo Opportunity, LLC Common Stock, par value $0.0001 per share | 5.1 | 8,995,979.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G | Open filing 0001213900-25-111134 Dispute this row |
| Vivo Opportunity Cayman Fund, L.P. Common Stock, par value $0.0001 per share | 0.3 | 549,487.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G | Open filing 0001213900-25-111134 Dispute this row |
| Vivo Opportunity Cayman, LLC Common Stock, par value $0.0001 per share | 0.3 | 549,487.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G | Open filing 0001213900-25-111134 Dispute this row |
| TANG CAPITAL MANAGEMENT, LLC Common Stock, par value $0.0001 per share | 9.99 | 17,176,510.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001214659-25-016681 Dispute this row |
| KEVIN TANG Common Stock, par value $0.0001 per share | 9.99 | 17,176,510.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001214659-25-016681 Dispute this row |
| TANG CAPITAL PARTNERS, LP Common Stock, par value $0.0001 per share | 5.98 | 10,274,944.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001214659-25-016681 Dispute this row |
| TANG CAPITAL PARTNERS INTERNATIONAL, LP Common Stock, par value $0.0001 per share | 3.24 | 5,568,566.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001214659-25-016681 Dispute this row |
| TANG CAPITAL PARTNERS III, INC Common Stock, par value $0.0001 per share | 0.58 | 999,750.00 | 09/30/2025 Filed 2025-11-14 | SCHEDULE 13G/AAmendment 3 | Open filing 0001214659-25-016681 Dispute this row |
Percent is of the class the filing names, as the holder stated it. Members of a group each report the group’s shares, so rows are not added together.
What was read
2,039,221 filings read, dated 2004-06-14 to 2026-11-13: Forms 3, 3/A, 4, 4/A, 5, 5/A.
Years can be incomplete while the archive is still being read. A year with few filings here is not a statement that few were made.
| Filing year | Filings read |
|---|---|
| 2015 | 1 |
| 2016 | 204,322 |
| 2017 | 202,494 |
| 2018 | 202,048 |
| 2019 | 193,638 |
| 2020 | 144,184 |
| 2021 | 224,474 |
| 2022 | 40,015 |
| 2023 | 199,811 |
| 2024 | 132,910 |
| 2025 | 235,520 |
| 2026 | 254,026 |
Filings made before the SEC required XML are listed, not extracted.